For the drug discovery, and wider pharmaceutical industry, the year of 2025 can be characterised by the words turmoil and uncertainty.   The second coming of President Trump brought with it a flurry of executive orders, tariffs and global bargaining that placed the US in a position where it attempted to dictate the terms of global imports […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!